Literature DB >> 21607970

Safety of influenza and H1N1 vaccinations in patients with myasthenia gravis, and patient compliance.

Eitan Auriel1, Keren Regev, Amir Dori, Arnon Karni.   

Abstract

Myasthenia gravis (MG) exacerbations may be triggered by infections.In the winter of 2009/2010, the Israeli Ministry of Health recommended that each individual with a chronic condition be vaccinated against both the seasonal influenza and the H1N1 virus. We examined vaccination practices in 74 MG patients. Only 38 patients (51.4%) received the seasonal influenza vaccine, and 24 (32.4%) received the H1N1 vaccine. No exacerbation of MG was found, and therefore seasonal influenza and H1N1 vaccines seem to be safe in MG.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21607970     DOI: 10.1002/mus.22077

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  10 in total

Review 1.  Laryngeal myasthenia gravis following influenza vaccination: a case report and literature review.

Authors:  Feng Wang; Tao Xiang; Lanying He; Jian Wang
Journal:  Hum Vaccin Immunother       Date:  2021-09-24       Impact factor: 4.526

Review 2.  Myasthenia gravis and infectious disease.

Authors:  Nils Erik Gilhus; Fredrik Romi; Yu Hong; Geir Olve Skeie
Journal:  J Neurol       Date:  2018-01-25       Impact factor: 4.849

3.  Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis.

Authors:  Itay Lotan; Mark A Hellmann; Yitzhak Friedman; Hadas Stiebel-Kalish; Israel Steiner; Adi Wilf-Yarkoni
Journal:  Neuromuscul Disord       Date:  2022-02-05       Impact factor: 4.296

Review 4.  TREATMENT OF MYASTHENIA GRAVIS PATIENTS WITH COVID-19: REVIEW OF THE LITERATURE.

Authors:  Sven Županić; Ines Lazibat; Maja Rubinić Majdak; Mia Jeličić
Journal:  Acta Clin Croat       Date:  2022-02       Impact factor: 0.932

Review 5.  Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients.

Authors:  Giulio Sansone; Domenico Marco Bonifati
Journal:  J Neurol       Date:  2022-05-03       Impact factor: 6.682

6.  BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves.

Authors:  Alon Doron; Yoav Piura; Ifat Vigiser; Hadar Kolb; Keren Regev; Nahum Nesher; Arnon Karni
Journal:  J Neurol       Date:  2022-07-30       Impact factor: 6.682

7.  Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study.

Authors:  Hong-Yan Li; Li-Yuan Shao; Min Song; Shi-Min Hu; Yao-Xian Yue; Hai-Feng Li
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786

8.  Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis.

Authors:  David Reyes-Leiva; Joaquín López-Contreras; Esther Moga; Francesc Pla-Juncà; Elionor Lynton-Pons; Ricardo Rojas-Garcia; Janina Turon-Sans; Luis Querol; Montse Olive; Rodrigo Álvarez-Velasco; Marta Caballero-Ávila; Álvaro Carbayo; Ana Vesperinas-Castro; Pere Domingo; Isabel Illa; Eduard Gallardo; Elena Cortés-Vicente
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-06-21

9.  Acetylcholine Receptor Antibody Titers and Clinical Course after Influenza Vaccination in Patients with Myasthenia Gravis: A Double-Blind Randomized Controlled Trial (ProPATIent-Trial).

Authors:  Björn Tackenberg; Maximilian Schneider; Franz Blaes; Christian Eienbröker; Carmen Schade-Brittinger; Anne Wellek; Marcus Deschauer; Markus Eickmann; Hans-Dieter Klenk; Hans-Helge Müller; Norbert Sommer
Journal:  EBioMedicine       Date:  2018-01-10       Impact factor: 8.143

10.  The Impacts of Influenza Infection and Vaccination on Exacerbation of Myasthenia Gravis.

Authors:  Hung Youl Seok; Ha Young Shin; Jong Kuk Kim; Byoung Joon Kim; Jeeyoung Oh; Bum Chun Suh; Sun Young Kim; Sa Yoon Kang; Suk Won Ahn; Jong Seok Bae; Byung Jo Kim
Journal:  J Clin Neurol       Date:  2017-10       Impact factor: 3.077

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.